These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 8435664)
1. A novel approach to immunomodulation of frozen human bone marrow with interleukin-2 for clinical application. Charak BS; Areman EM; Dickerson SA; Choudhary GD; Sacher R; Kotula PL; Brown EG; Mazumdar A Bone Marrow Transplant; 1993 Feb; 11(2):147-54. PubMed ID: 8435664 [TBL] [Abstract][Full Text] [Related]
2. A novel approach to purging of leukemia by activation of bone marrow with interleukin 2. Charak BS; Malloy B; Agah R; Mazumder A Bone Marrow Transplant; 1990 Sep; 6(3):193-8. PubMed ID: 2252959 [TBL] [Abstract][Full Text] [Related]
3. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Klingemann HG; Deal H; Reid D; Eaves CJ Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 (IL-2) and IL-2-activated bone marrow in transplantation: evaluation from a clinical perspective. Charak BS; Agah R; Brynes RK; Chogyoji M; Groshen S; Chen SC; Mazumder A Bone Marrow Transplant; 1992 Jun; 9(6):479-86. PubMed ID: 1628133 [TBL] [Abstract][Full Text] [Related]
5. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12. Wong EK; Eaves C; Klingemann HG Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 in bone marrow transplantation: preclinical studies. Charak BS; Choudhary GD; Tefft M; Mazumder A Bone Marrow Transplant; 1992 Aug; 10(2):103-11. PubMed ID: 1326364 [TBL] [Abstract][Full Text] [Related]
8. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice. Agah R; Malloy B; Kerner M; Girgis E; Bean P; Twomey P; Mazumder A Cancer Res; 1989 Nov; 49(21):5959-63. PubMed ID: 2790810 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Verma UN; Areman E; Dickerson SA; Kotula PL; Sacher R; Mazumder A Bone Marrow Transplant; 1995 Feb; 15(2):199-206. PubMed ID: 7773209 [TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. Agah R; Malloy B; Kerner M; Mazumder A J Immunol; 1989 Nov; 143(9):3093-9. PubMed ID: 2809219 [TBL] [Abstract][Full Text] [Related]
12. Bacterial contamination of autologous bone marrow: reinfusion of culture-positive grafts does not result in clinical sequelae during the posttransplantation course. Schwella N; Rick O; Heuft HG; Miksits K; Zimmermann R; Zingsem J; Eckstein R; Huhn D Vox Sang; 1998; 74(2):88-94. PubMed ID: 9501406 [TBL] [Abstract][Full Text] [Related]
13. In vitro generation of natural killer cells from SJL/J bone marrow precursors. D'Adamio L; Cannarile L; Migliorati G; Riccardi C J Biol Regul Homeost Agents; 1988; 2(2):71-6. PubMed ID: 3263749 [TBL] [Abstract][Full Text] [Related]
15. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation. Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points. Verma UN; Mazumder A Bone Marrow Transplant; 1995 Sep; 16(3):365-72. PubMed ID: 8535308 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation. Porrata LF; Inwards DJ; Lacy MQ; Markovic SN Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790 [TBL] [Abstract][Full Text] [Related]
18. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941 [TBL] [Abstract][Full Text] [Related]
19. Cryopreservation of human bone marrow after purging T-cells or tumor cells. Zhang ZX; Xu YJ; Chen Y; Li Y; Shen BF; Bai Y Cryobiology; 1994 Oct; 31(5):478-82. PubMed ID: 7988157 [TBL] [Abstract][Full Text] [Related]
20. [Study of anti-myeloma activity of interleukin-2 activated bone marrow in vitro]. Liu W; Chen SL; Liu JW; Li X; Xia CQ; Qi M Zhonghua Xue Ye Xue Za Zhi; 2005 Apr; 26(4):205-8. PubMed ID: 15949260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]